Tissue factor-targeted antibody-drug conjugate

Patent metadata

Field	Value
Publication number	US-12290505-B2
Application number	US-202218050240-A
Country	US
Kind code	B2
Filing date	Oct 27, 2022
Priority date	Aug 22, 2016
Publication date	May 6, 2025
Grant date	May 6, 2025

Abstract

A tissue factor (TF)-targeted antibody-drug conjugate (ADC) and a method for preparing the ADC. The ADC is capable of binding to TF antigen with high specificity, and has high affinity, low immunogenicity, high cytotoxicity, and significant anti-tumor activity.

First claim

The invention claimed is:

1. A method for treating a tissue factor (TF)-related disease, comprising administering a therapeutically effective amount of the antibody-drug conjugate or a pharmaceutical composition comprising the antibody-drug conjugate to a subject in need thereof,
wherein the antibody-drug conjugate comprises:
(a) an antibody moiety, wherein the heavy chain variable region of the antibody comprises the following three complementary determining regions (CDRs):
(H1) CDR1 as set forth in SEQ ID NO: 1,
(H2) CDR2 as set forth in SEQ ID NO: 2, and
(H3) CDR3 as set forth in SEQ ID NO: 3, and
the light chain variable region of the antibody comprises the following three complementary determining regions (CDRs):
(L1) CDR1′ as set forth in SEQ ID NO: 4,
(L2) CDR2′ as set forth in SEQ ID NO: 5, and
(L3) CDR3′ as set forth in SEQ ID NO: 6, and

(b) a conjugation moiety conjugated to the antibody moiety, wherein the conjugation moiety is Monomethyl auristatin E (MMAE); and
wherein the TF-related disease is tumorigenesis, tumor growth, or tumor metastasis, the tumor is a tumor with high TF expression, and the tumor is pancreatic cancer, triple negative breast cancer, cervical cancer, lung cancer or malignant glioma.

2. The method according to claim 1 , wherein the antibody-drug conjugate (ADC) has a formula as follows:

wherein:
Ab is an anti-TF antibody,
LU is a linker;
D is the conjugate moiety;
and the subscript p is a value selected from 1-10.

3. The method according to claim 1 , wherein the antibody is an animal-derived antibody, a chimeric antibody, a humanized antibody, or a combination thereof.

4. The method according to claim 1 , wherein the sequence of the heavy chain variable region of the antibody is selected from the group consisting of SEQ ID NOS: 7, 9, 10, 11, 12, and 13.

5. The method according to claim 1 , wherein the sequence of the light chain variable region of the antibody is selected from the group consisting of SEQ IDS NO: 8, 14, 15, 16, and 17.

6. The method according to claim 4 , wherein the sequence of the light chain variable region of the antibody is selected from the group consisting of SEQ IDS NO: 8, 14, 15, 16, and 17.

7. The method according to claim 1 , wherein the antibody is selected from the group consisting of TF-mAb-SC1, TF-mAb-Ch, TF-mAb-H29, TF-mAb-H30, TF-mAb-H31, TF-mAb-H32, TF-mAb-H33, TF-mAb-H34, TF-mAb-H35, TF-mAb-H36, TF-mAb-H37, TF-mAb-H38, TF-mAb-H39, TF-mAb-H40, TF-mAb-H41, TF-mAb-H42, TF-mAb-H43, TF-mAb-H44, TF-mAb-H45, TF-mAb-H46, TF-mAb-H47, and TF-mAb-H48.

8. The method according to claim 1 , wherein the antibody is TF-mAb-H39 or TF-mAb-H44.

9. The method according to claim 1 , wherein the tumor is triple negative breast cancer.

10. The method according to claim 1 , wherein the tumor is pancreatic cancer.

11. The method according to claim 1 , wherein the tumor is cervical cancer.

12. The method according to claim 1 , wherein the tumor is lung cancer.

13. The method according to claim 1 , wherein the tumor is malignant glioma.

Assignees

• Univ Fudan
• Shanghai Inst Materia Medica Cas
• Shanghai Miracogen Inc

Inventors

• Yu Ke
• Shen Jingkang
• Meng Tao
• Ma Lanping
• Zhang Xuesai
• Li Qingrou
• Lin Qing

Classifications

• C07K2317/90

  characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• A61K31/5365

  ortho- or peri-condensed with heterocyclic ring systems · CPC title

• A61K31/4025

  not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title